This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today provided an overview of selected studies that will be presented at the 52
nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place from September 9
th to 12
th in San Francisco.
The studies focus on the company’s lead investigational antibiotics, CXA-201 and CB-315, basic science research as well as the marketed antibiotic, CUBICIN® (daptomycin for injection).
“The breadth of presentations at ICAAC shows how we are advancing science to not only inform the appropriate use of CUBICIN but also to discover and develop new antibiotics for serious and potentially life-threatening infections,” said Steve Gilman, PhD, Chief Scientific Officer at Cubist Pharmaceuticals. “We’re excited that our lead pipeline antibiotics are now in pivotal Phase 3 trials and we hope to one day make them available to doctors and patients who deal with the challenge of emerging resistant infections.”
A list of selected presentations can be found on the company’s
website. Key highlights include:
CXA-201, a novel cephalosporin in combination with tazobactam, is in development for the treatment of certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms, particularly
Pseudomonas aeruginosa and those in the Enterobacteriaceae family.
This year at ICAAC, six studies on CXA-201 will be presented. In one important study, CXA-201 showed greater potency than currently available anti-
Pseudomonas aeruginosa cephalosporins (ceftazidime and cefepime) and piperacillin/tazobactam when tested against
Pseudomonas aeruginosa and Enterobacteriaceae strains from hospitals in the United States.
Activity of the Novel Antimicrobial Ceftolozane/Tazobactam Tested Against Contemporary Clinical Strains from USA Hospitals (2011) (Abstract E-199) Sunday, September 9, 2012, 11:30 a.m. - 1:30 p.m. PDT, Halls A-C.
CB-315, a novel oral antibiotic, is in development for the treatment for
Clostridium difficile-associated diarrhea, or CDAD.
Clostridium difficile causes diarrhea linked to 14,000 American deaths each year. This year the company initiated pivotal Phase 3 studies of CB-315, and
in vitro data at ICAAC will show that
Clostridium difficile is more susceptible to CB-315 than to other antibiotics like vancomycin and moxifloxacin.
Susceptibilities of Clostridium difficile
to CB-183,315 and Comparators (Abstract E-807) Monday, September 10, 2012, 11:15 a.m. - 1:15 p.m. PDT, Halls A-C.
Several abstracts on basic science and drug discovery efforts will be presented at the meeting. One of these focuses on CB-027, which is a novel broad spectrum cephalosporin with potent
in vitro activities against both Gram-positive and Gram-negative bacteria. This includes methicillin-resistant
Staphylococcus aureus (MRSA) and
Pseudomonas aeruginosa. In this animal study, CB-027 showed potent
in vivo activity against several drug-resistant strains, including MRSA, ceftazidime-resistant
Pseudomonas aeruginosa and
Efficacy of CB-027 against Methicillin-Resistant Staphylococcus aureus
, and Ceftazidime-Resistant Pseudomonas aeruginosa
and Klebsiella pneumoniae
Infections in Mice (Abstract F-846) Monday, September 10, 2012, 11:15 a.m. - 1:15 p.m. PDT, Halls A-C.
CUBICIN (daptomycin for injection)
More than 30 scientific abstracts at ICAAC feature data on daptomycin. Importantly in an oral presentation, new data will show that early use of daptomycin significantly lowers rates of clinical failure, including both 90-day mortality and microbiological failure compared to vancomycin for infections caused by certain strains (VAN MIC > 1 mg/L) of MRSA.